Verve Therapeutics (VERV) Stock Chart & Stock Price History $5.19 -0.31 (-5.64%) Closing price 05/2/2025 04:00 PM EasternExtended Trading$5.24 +0.05 (+1.06%) As of 05/2/2025 07:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Chart Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock Verve Therapeutics Stock Price Performance 5 Day Performance-9.42%1 Month Performance+34.81%3 Month Performance-30.98%6 Month Performance-12.48%Year-To-Date Performance-7.98%1 Year Performance-19.03% Receive VERV Stock News and Ratings via EmailSign-up to receive the latest news and ratings for Verve Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address VERV Stock Chart for Saturday, May, 3, 2025 VERV Chart by TradingView Verve Therapeutics Stock Price History Daily Weekly Monthly Time Frame Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year Time Frame * Start Date * End Date Export to Excel DateOpening PriceClosing PriceHighLowVolumeMarket Capitalization05/02/2025$5.50$5.19-5.64%$5.68$5.162.92 million shs$462.65 million05/01/2025$5.67$5.50-3.00%$5.75$5.322.19 million shs$490.29 million04/30/2025$5.46$5.67+3.85%$5.75$5.302.06 million shs$503.47 million04/29/2025$5.73$5.46-4.71%$5.73$5.402.14 million shs$484.83 million04/28/2025$5.76$5.73-0.52%$6.10$5.652.25 million shs$508.80 million04/25/2025$5.78$5.76-0.35%$5.92$5.631.66 million shs$511.47 million04/24/2025$5.47$5.78+5.67%$5.94$5.373.05 million shs$513.24 million04/23/2025$5.25$5.47+4.19%$5.96$5.454.58 million shs$485.71 million04/22/2025$4.78$5.25+9.83%$5.31$4.784.02 million shs$466.18 million04/21/2025$4.59$4.78+4.14%$5.50$4.375.60 million shs$424.45 million Get the Latest News and Ratings for VERV and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Verve Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 04/18/2025$4.59$4.59$4.84$4.432.59 million shs$407.57 million04/17/2025$4.51$4.59+1.77%$4.84$4.432.59 million shs$407.57 million04/16/2025$4.97$4.51-9.26%$4.95$4.277.06 million shs$400.47 million04/15/2025$4.12$4.97+20.63%$5.81$4.8824.47 million shs$441.32 million04/14/2025$3.26$4.12+26.38%$4.30$3.5531.85 million shs$365.84 million04/11/2025$3.05$3.26+6.89%$3.31$3.052.38 million shs$289.48 million04/10/2025$3.41$3.05-10.56%$3.31$2.941.96 million shs$270.83 million04/09/2025$2.97$3.41+14.81%$3.53$2.864.10 million shs$302.79 million04/09/2025$2.97$3.41+14.81%$3.53$2.864.10 million shs$302.79 million04/08/2025$3.34$2.97-11.08%$3.61$2.912.34 million shs$263.72 million04/08/2025$3.34$2.97-11.08%$3.61$2.912.34 million shs$263.72 million04/07/2025$3.62$3.34-7.73%$3.63$3.103.28 million shs$296.58 million04/04/2025$3.85$3.62-5.97%$3.74$3.462.17 million shs$321.44 million04/03/2025$3.91$3.85-1.53%$3.96$3.682.48 million shs$341.87 million04/02/2025$4.14$3.91-5.56%$4.42$3.772.59 million shs$347.19 million Related Companies Bausch Health Companies Stock Chart Beam Therapeutics Stock Chart Gemini Therapeutics Stock Chart NewAmsterdam Pharma Stock Chart Vericel Stock Chart Belite Bio Stock Chart Tarsus Pharmaceuticals Stock Chart Janux Therapeutics Stock Chart Schrödinger Stock Chart Arrowhead Pharmaceuticals Stock Chart Receive VERV Stock News and Ratings via EmailSign-up to receive the latest news and ratings for Verve Therapeutics and its competitors with MarketBeat's FREE daily newsletter. This page (NASDAQ:VERV) was last updated on 5/3/2025 by MarketBeat.com Staff From Our PartnersGold Alert: The Truth About Fort Knox Is ComingOwning physical gold isn’t the best way to profit. I’ve found a better way to invest in gold—one that’s alr...Golden Portfolio | SponsoredElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | SponsoredTrump to solve American wealth loss?Is President Trump’s Executive Order 14179… A secret way to restore wealth for good citizens? If you’ve ...Paradigm Press | SponsoredNow I look stupid. Real stupid... I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredThe collapse has already startedThe headlines scream tariffs and export bans — but the real damage is happening in retirement portfolios. Tim ...Investors Alley | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredSecret financial plot unfolding in Washington DC… [DEVELOPING]What stocks are next up to soar in 2025? I believe I’ve found the answer - and it might surprise you. Yo...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Verve Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Verve Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
